Plasma lipoprotein(a) levels in subjects attending a metabolic ward: Discrimination between individuals with and without a history of ischemic stroke

Maurizio Margaglione, Giovanni DiMinno, Elvira Grandone, Egidio Celentano, Gennaro Vecchione, Giuseppe Cappucci, Massimo Grilli, Francesco Paolo Mancini, Alfredo Postiglione, Salvatore Panico, Mario Mancini

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

In this cross-sectional study we compared the abilities of lipoprotein(a) [Lp(a)], plasminogen activator inhibitor-1 (PAI- 1), and tissue plasminogen activator (TPA) to discriminate between individuals with and without a history of stroke from among subjects in a metabolic ward. A total of 210 subjects (108 men and 102 women: mean age, 63.8 years; range, 31 to 86 years) provided plasma and DNA samples for the study. Of these, 51 men and 50 women had a history of ischemia stroke. The 109 subjects without a history of stroke were compared with those with such a history for major risk factors for ischemic events. Mean plasma TPA and PAI- 1 levels significantly (P50 mg/dL were more common among stroke patients (8 with versus 1 without, P2 test). A molecular variation in the 5' flanking region of the apo(a) gene that has been related to elevated Lp(a) plasma levels (G/A-914) was not strongly correlated with circulating levels of Lp(a), nor did Lp(a) levels correlate with a polymorphism of the apo(a) gene (G/A-21), which is strongly linked (P50 mg/dL) plasma levels of the lipoprotein.

Original languageEnglish
Pages (from-to)120-128
Number of pages9
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume16
Issue number1
Publication statusPublished - 1996

Fingerprint

Lipoprotein(a)
Stroke
Plasminogen Activator Inhibitor 1
Tissue Plasminogen Activator
5' Flanking Region
Genes
Lipoproteins
Ischemia
Cross-Sectional Studies
History
DNA

Keywords

  • fibrinolytic variables
  • genotype
  • ischemic stroke
  • lipoprotein(a)

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Plasma lipoprotein(a) levels in subjects attending a metabolic ward : Discrimination between individuals with and without a history of ischemic stroke. / Margaglione, Maurizio; DiMinno, Giovanni; Grandone, Elvira; Celentano, Egidio; Vecchione, Gennaro; Cappucci, Giuseppe; Grilli, Massimo; Mancini, Francesco Paolo; Postiglione, Alfredo; Panico, Salvatore; Mancini, Mario.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 16, No. 1, 1996, p. 120-128.

Research output: Contribution to journalArticle

Margaglione, M, DiMinno, G, Grandone, E, Celentano, E, Vecchione, G, Cappucci, G, Grilli, M, Mancini, FP, Postiglione, A, Panico, S & Mancini, M 1996, 'Plasma lipoprotein(a) levels in subjects attending a metabolic ward: Discrimination between individuals with and without a history of ischemic stroke', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 16, no. 1, pp. 120-128.
Margaglione, Maurizio ; DiMinno, Giovanni ; Grandone, Elvira ; Celentano, Egidio ; Vecchione, Gennaro ; Cappucci, Giuseppe ; Grilli, Massimo ; Mancini, Francesco Paolo ; Postiglione, Alfredo ; Panico, Salvatore ; Mancini, Mario. / Plasma lipoprotein(a) levels in subjects attending a metabolic ward : Discrimination between individuals with and without a history of ischemic stroke. In: Arteriosclerosis, Thrombosis, and Vascular Biology. 1996 ; Vol. 16, No. 1. pp. 120-128.
@article{826fbd17e54e4e718ee78d35fdb30411,
title = "Plasma lipoprotein(a) levels in subjects attending a metabolic ward: Discrimination between individuals with and without a history of ischemic stroke",
abstract = "In this cross-sectional study we compared the abilities of lipoprotein(a) [Lp(a)], plasminogen activator inhibitor-1 (PAI- 1), and tissue plasminogen activator (TPA) to discriminate between individuals with and without a history of stroke from among subjects in a metabolic ward. A total of 210 subjects (108 men and 102 women: mean age, 63.8 years; range, 31 to 86 years) provided plasma and DNA samples for the study. Of these, 51 men and 50 women had a history of ischemia stroke. The 109 subjects without a history of stroke were compared with those with such a history for major risk factors for ischemic events. Mean plasma TPA and PAI- 1 levels significantly (P50 mg/dL were more common among stroke patients (8 with versus 1 without, P2 test). A molecular variation in the 5' flanking region of the apo(a) gene that has been related to elevated Lp(a) plasma levels (G/A-914) was not strongly correlated with circulating levels of Lp(a), nor did Lp(a) levels correlate with a polymorphism of the apo(a) gene (G/A-21), which is strongly linked (P50 mg/dL) plasma levels of the lipoprotein.",
keywords = "fibrinolytic variables, genotype, ischemic stroke, lipoprotein(a)",
author = "Maurizio Margaglione and Giovanni DiMinno and Elvira Grandone and Egidio Celentano and Gennaro Vecchione and Giuseppe Cappucci and Massimo Grilli and Mancini, {Francesco Paolo} and Alfredo Postiglione and Salvatore Panico and Mario Mancini",
year = "1996",
language = "English",
volume = "16",
pages = "120--128",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Plasma lipoprotein(a) levels in subjects attending a metabolic ward

T2 - Discrimination between individuals with and without a history of ischemic stroke

AU - Margaglione, Maurizio

AU - DiMinno, Giovanni

AU - Grandone, Elvira

AU - Celentano, Egidio

AU - Vecchione, Gennaro

AU - Cappucci, Giuseppe

AU - Grilli, Massimo

AU - Mancini, Francesco Paolo

AU - Postiglione, Alfredo

AU - Panico, Salvatore

AU - Mancini, Mario

PY - 1996

Y1 - 1996

N2 - In this cross-sectional study we compared the abilities of lipoprotein(a) [Lp(a)], plasminogen activator inhibitor-1 (PAI- 1), and tissue plasminogen activator (TPA) to discriminate between individuals with and without a history of stroke from among subjects in a metabolic ward. A total of 210 subjects (108 men and 102 women: mean age, 63.8 years; range, 31 to 86 years) provided plasma and DNA samples for the study. Of these, 51 men and 50 women had a history of ischemia stroke. The 109 subjects without a history of stroke were compared with those with such a history for major risk factors for ischemic events. Mean plasma TPA and PAI- 1 levels significantly (P50 mg/dL were more common among stroke patients (8 with versus 1 without, P2 test). A molecular variation in the 5' flanking region of the apo(a) gene that has been related to elevated Lp(a) plasma levels (G/A-914) was not strongly correlated with circulating levels of Lp(a), nor did Lp(a) levels correlate with a polymorphism of the apo(a) gene (G/A-21), which is strongly linked (P50 mg/dL) plasma levels of the lipoprotein.

AB - In this cross-sectional study we compared the abilities of lipoprotein(a) [Lp(a)], plasminogen activator inhibitor-1 (PAI- 1), and tissue plasminogen activator (TPA) to discriminate between individuals with and without a history of stroke from among subjects in a metabolic ward. A total of 210 subjects (108 men and 102 women: mean age, 63.8 years; range, 31 to 86 years) provided plasma and DNA samples for the study. Of these, 51 men and 50 women had a history of ischemia stroke. The 109 subjects without a history of stroke were compared with those with such a history for major risk factors for ischemic events. Mean plasma TPA and PAI- 1 levels significantly (P50 mg/dL were more common among stroke patients (8 with versus 1 without, P2 test). A molecular variation in the 5' flanking region of the apo(a) gene that has been related to elevated Lp(a) plasma levels (G/A-914) was not strongly correlated with circulating levels of Lp(a), nor did Lp(a) levels correlate with a polymorphism of the apo(a) gene (G/A-21), which is strongly linked (P50 mg/dL) plasma levels of the lipoprotein.

KW - fibrinolytic variables

KW - genotype

KW - ischemic stroke

KW - lipoprotein(a)

UR - http://www.scopus.com/inward/record.url?scp=9044247066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9044247066&partnerID=8YFLogxK

M3 - Article

C2 - 8548412

AN - SCOPUS:9044247066

VL - 16

SP - 120

EP - 128

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 1

ER -